Articles: coronavirus.
-
Data sources Narrative reviewStudy abstract This review provides a synopsis of our understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated coronavirus disease, COVID-19. The virus is shed in the nasopharyngeal and salivary secretions of carriers, and this puts dental professionals at risk for increased exposure of SARS-CoV-2. The paper summarises the current guidelines outlined by the CDC and presents the triaging protocols to identify potential carriers and how to safely limit treatment to low-risk patients.
-
J Coll Physicians Surg Pak · Jun 2020
A Systematic Analysis of Studies on Corona Virus Disease 19 (COVID-19) from Viral Emergence to Treatment.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created tremendous panic around the globe amid rapid transmission and high mortality. The virus emerged from China in December 2019 and spread to over 200 countries. The number of cases in USA and Europe has surpassed that of China. ⋯ In this context, current manuscript is aimed to provide amalgamated information in a single document to healthcare professionals, researchers and the general public regarding the outbreak-turned-pandemic of COVID-19. This systematic review discusses epidemiology, pathogenesis, transmission, clinical manifestations, severity, treatment, prevention, vaccination, medication repositioning, potential drug candidates, and control and public awareness of COVID-19. Key Words: COVID-19, Pandemic, Epidemiology, Virology, SARS-CoV-2, World Health Organization, Corona Virus.
-
Coronavirus disease 2019 (COVID-19), which was previously known as 2019-novel coronavirus (2019-nCoV), was first reported in Wuhan, China in December 2019. The disease evolved into a serious global emergency, leading to its declaration as a pandemic. ⋯ There is an urgent need to put into perspective these realities peculiar to Africa including Nigeria and explore available collective measures and interventions to address the COVID-19 pandemic.
-
We present a case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical intensive care unit of a community teaching hospital. A previously healthy 40-year-old man was admitted to the hospital 3 days after the onset of coronavirus disease 2019 (COVID-19) symptoms including dry cough, fever, and shortness of breath progressing to intubation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID-19 polymerase chain reaction result. ⋯ Sixty hours after initiating remdesivir, the patient was successfully extubated and able to transition to room air within 24 hours of extubation. Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals utilized for different disease states, such as oseltamivir, that are most effective when started as soon as possible following symptom onset. Urgent action is needed by regulatory agencies to work with drug manufacturers to expedite the study and approval of investigational agents targeting SARS-CoV-2 as well as to meet manufacturing demands.
-
Since December 2019, a series of unexplained pneumonia cases have been reported in Wuhan, China. On 12 January 2020, the World Health Organization (WHO) temporarily named this new virus as the 2019 novel coronavirus (2019-nCoV). ⋯ The COVID-19 epidemic is spreading all over the world, especially in China. Based on the published evidence, we systematically discuss the characteristics of COVID-19 in the hope of providing a reference for future studies and help for the prevention and control of the COVID-19 epidemic.